1 completed, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow LY2510924: new trials by email Literature Review of LY2510924 trials Research Report on LY2510924
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY2510924 and Durvalumab in Participants With Solid Tumors LY2510924, Durvalumab - Solid Tumor | Phase 1 | Terminated | Eli Lilly and Company | 9 | 2016-09-01 | 2019-08-12 |
| LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia LY2510924, Idarubicin, Cytarabine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 36 | 2016-05-09 | 2019-11-15 |
Leukemia (1) · Leukemia, Myeloid, Acute (1) · Recurrence (1)
Eli Lilly and Company (1) · M.D. Anderson Cancer Center (1)
United States (1)